Paper Details

  1. Home
  2. Paper Details

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Author: AquinoSara, BallantiStelvio, BelottiAngelo, BertaminiLuca, BoccadoroMario, CapraAndrea, CavoMichele, CeaMichele, CorradiniPaolo, D'AgostinoMattia, GalliMonica, GamberiBarbara, GayFrancesca, GiulianiNicola, GrassoMariella, LeddaAntonio, MustoPellegrino, OffidaniMassimo, PalmasAngelo, PatriarcaFrancesca, PetrucciMaria Teresa, Rota-ScalabriniDelia, SpadanoAntonio, ZamagniElena, ZambelloRenato, de FabritiisPaolo

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated different carfilzomib-based induction and consolidation approaches for treating newly diagnosed multiple myeloma. The current standard of care for young and fit patients is bortezomib-based induction followed by high-dose melphalan and autologous stem-cell transplantation. This study explored alternative treatment strategies involving carfilzomib and lenalidomide.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Bortezomib-based induction followed by high-dose melphalan (200 mg/m<sup>2</sup>) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myelo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(21)00535-0

データ提供：米国国立医学図書館（NLM）

FORTE: A New Frontier in Multiple Myeloma Treatment

Multiple myeloma is a complex and challenging cancer that affects plasma cells in the bone marrow. This research investigates the efficacy and safety of different carfilzomib-based treatment approaches for newly diagnosed multiple myeloma patients. The study compared various combinations of carfilzomib, cyclophosphamide, dexamethasone, lenalidomide, and autologous stem-cell transplantation in a randomized, open-label, phase 2 trial. The researchers aimed to determine the optimal treatment strategy for these patients and evaluate the long-term outcomes.

Navigating the Sands of Multiple Myeloma Treatment

The study revealed that carfilzomib-based induction and consolidation approaches, with or without transplantation, showed promising results in treating newly diagnosed multiple myeloma. The different treatment combinations demonstrated varying levels of effectiveness, with some achieving deeper responses and longer durations of remission. The study also highlighted the importance of maintenance therapy with carfilzomib plus lenalidomide or lenalidomide alone, which contributed to sustained remission and improved survival outcomes. It's like a camel traversing the desert, strategically choosing its route and adapting its strategies to navigate the challenges ahead.

A Beacon of Hope for Multiple Myeloma Patients

The findings of this study offer a beacon of hope for patients with multiple myeloma. The research suggests that carfilzomib-based therapies, combined with appropriate supportive care, can significantly improve outcomes and extend survival. It's a reminder that ongoing research and clinical trials are essential for advancing treatment options and improving the lives of patients with this challenging disease. Remember, never give up hope and always seek out the latest information and treatment options available.

Dr.Camel's Conclusion

This study is a testament to the dedication of researchers in the fight against cancer. By exploring new treatment strategies and refining existing approaches, we can offer patients with multiple myeloma a better chance for a longer and healthier life. It's a journey through the vast desert of cancer research, searching for oases of hope and breakthroughs that can transform the lives of patients.

Date :
  1. Date Completed 2022-01-10
  2. Date Revised 2022-01-10
Further Info :

Pubmed ID

34774221

DOI: Digital Object Identifier

10.1016/S1470-2045(21)00535-0

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.